Track 12: Value and Access

The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders – providers, payers, biopharma, and ultimately patients. The Value and Access track will bring together global regulators, industry leaders, patients, and payers who will facilitate discussions and address questions such as:

• What information and evidence is being used to define value?
• Who is making or influencing access decisions?
• How can real-world data be leveraged to drive access to medicines?
• What are the regulatory and legal considerations surrounding value-based contracting conversations with payers?

Sessions in Value and Access

Monday, June 15

• Outcomes as a Pathway to Value and Pharma, Payer, Provider Collaboration
• Should a COVID-19 Vaccination be Legally Mandated and Can HTA Inform That Decision?

Tuesday, June 16

• On the Soapbox: At a Time of High Priced Medicines and a Global Pandemic - How Do We Make Medicines Accessible and Affordable to All?

Wednesday, June 17

• Recommendations for a Strategic Response to the COVID-19 Pandemic
• Drug Pricing in the United States: How and Why is it Different than in the Rest of the World

On Demand

• Communicating Value to Payers Pre-Approval in the US
• Considerations for Long-Term Outcomes Data Collection for Value-Based Payment Arrangements
• Subscription Models to Incentive Antimicrobial Innovation
• Real World Use of Real World Evidence

Who is This Track Designed For?

Professionals involved in: Health economics outcomes, statistics, data modeling, clinical research, post-marketing, regulatory affairs, and health economy.

View Other Tracks

Registration Rates

Back to DIA 2020

Back to DIAglobal.org